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Overexpression of the small GTPase, RhoC, in various human cancers has been correlated with high metastatic
ability and poor prognosis. Rho-kinase (ROCK) is an important effector of Rho GTPases. The oncogenic serine/
threonine kinase Akt (also known as PKB) is a downstream effector of phosphatidylinositol-3 kinase (PI3K). Akt
activation contributes to the neoplastic phenotype by promoting cell cycle progression, increasing
antiapoptotic functions, and enhancing tumor cell invasion. Rho signaling via ROCK has been previously
shown either to activate or to downregulate PI3K/Akt. Using a human radial growth phase melanoma cell line,
WM35, we have established stable transfectants that overexpress RhoC (called WM35RhoC). We found that
overexpression of RhoC increased phosphorylated-Akt (Ser473/474/472, pAkt) expression and promoted cell
invasion. Inhibition of RhoC with C3 transferase downregulated pAkt expression and decreased cell invasion in
these cells. In addition, inhibition of PI3K, Akt, or ROCK partially decreased invasion. Further, inhibition of PI3K
but not ROCK decreased the pAkt level. These results suggest that RhoC promotes invasion in part via activation
of a PI3K/Akt pathway, in a manner independent of ROCK signaling. We propose that RhoC promotes melanoma
progression via separate mechanisms that regulate the PI3K/Akt pathway and the ROCK signaling pathway.
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INTRODUCTION
Metastatic melanoma is highly resistant to all forms of
chemo-, immuno-, or radiation therapy. Despite its obvious
importance, the process of metastasis remains incompletely
characterized at the molecular and biochemical levels
(Fidler, 2002). More effective therapeutic regimes will require
better understanding of predominant gene alterations during
melanoma development or progression and specific targeting
of these defects.
Melanoma develops in well-defined stages with distinct
clinical, biological, and histological characteristics (Herlyn
et al., 1987). Beginning as an in situ tumor arising in a
common nevus, congenital nevus, or dysplastic nevus,
melanoma progresses through a slowly growing radial growth
phase (RGP), to a rapidly growing and invasive vertical
growth phase (VGP). During RGP or very early VGP, there is
only low metastatic potential, whereas late VGP has a high
risk for metastasis (Herlyn et al., 1987). The acquisition of
invasive properties is an important part of metastatic
progression.
Rho GTPases belong to the Ras superfamily of proteins. All
eucaryotes contain at least one Rho GTPase (Karnoub et al.,
2004). The 22 known Rho family members fall into four main
subfamilies: Rho, Rac, Cdc42, and others that lack GTPase
activity (Sahai and Marshall, 2002a, b). Unlike Ras, no
activating mutations have been observed for Rho family
GTP-binding proteins in cancer. However, there is increasing
evidence that overexpression of Rho family members and/or
dysregulation of their GDP-GTP cycle play an important
role in cancer development and progression. Rho family
members have been implicated at multiple stages in
tumorigenesis and progression. Activation of these GTPases
can induce several intracellular signaling cascades, impact-
ing various cellular responses, including reorganization of the
actin cytoskeleton, gene transcription, survival, and prolif-
eration (see for review Sahai and Marshall, 2002a, b).
Although RhoA, RhoB, and RhoC share 85% amino-acid
sequence identity, they show preferential interactions with
some regulators and effectors that confer differences in
function in cells (see for review Wheeler and Ridley, 2004).
Clinically, RhoC overexpression has been correlated with
progression, invasion, and metastasis in many cancers,
including melanoma (Suwa et al., 1998; Horiuchi et al.,
2003; Shikada et al., 2003; Shinto et al., 2003; Wang et al.,
2003; Kondo et al., 2004). Overexpression of RhoC in murine
lung cancer cells enhanced their metastasis in an orthotopic
model in mice, as well as increased their in vitro migration
and invasion ability (Ikoma et al., 2004). Conversely, anti-
RhoC small interfering RNAs could inhibit the proliferation
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and invasiveness of MDA-MB-231 breast cancer cells in vitro
and in vivo (Pille et al., 2005). For melanoma, increased
RhoC expression was found to correlate with metastatic
behavior in an in vivo selection scheme, and overexpression
of RhoC in a VGP cell line promoted metastasis (Clark et al.,
2000). This high impact paper (Clark et al., 2000) and others
encouraged extensive studies of the role of RhoC and other
Rho proteins in melanoma metastasis.
Phosphatidylinositol-3 kinases (PI3Ks) and Akt (also
known PKB) signaling pathways are frequently activated in
many human cancers including melanoma (see for review
Testa and Bellacosa, 2001; also Bellacosa et al., 1995;
Brognard et al., 2001; Nakayama et al., 2001; Sun et al.,
2001; Stahl et al., 2003; Stahl et al., 2004). Activation of Akt
has been shown to enhance invasiveness and metastasis of
human melanoma, squamous cell carcinoma, and breast and
ovarian cancer cells (Thant et al., 2000; Park et al., 2001; Plas
et al., 2001; Dhawan et al., 2002; Nicholson and Anderson,
2002; Arboleda et al., 2003; Grille et al., 2003), indicating a
significant role for Akt in tumor progression, as well. This can
be due to gene amplification of Akt1, Akt2, or Akt3 in cancers
(Staal, 1987; Cheng et al., 1992; Bellacosa et al., 1995; Lu
et al., 1995; Cheng et al., 1996) or decrease of PTEN activity
(Stahl et al., 2004).
The three known isoforms of Akt all contain two major
regulatory sites of phosphorylation (Thr308 and Ser473 in
Akt1), essential for maximal Akt activation (see for review
Testa and Bellacosa, 2001). Negative regulation of the PI3K/
Akt pathway is mainly accomplished by the dual function
lipid and protein phosphatase PTEN (phosphatase and tensin
homologue deleted on chromosome 10). PTEN was originally
identified as a tumor suppressor and is frequently affected by
germline and somatic mutations in human cancers (Myers
and Tonks, 1997; Cantley and Neel, 1999).
Rho-kinase (ROCK) is one of the most important Rho
effectors (see for review Chardin, 2003). Rho (RhoA was the
main one studied) and ROCK have been shown to participate
in diverse cellular signaling functions such as smooth muscle
contraction, cytoskeleton rearrangement, and cell migration
and proliferation. In the inactive form, ROCK seems to be
autoinhibited in a closed conformation. The binding of RhoA,
RhoB, or RhoC to a central Rho-binding domain relieves this
autoinhibition and leads to activation of ROCK (see for
review Chardin, 2003). Protein interaction studies suggest
that ROCK has a higher affinity for RhoC compared to RhoA
and RhoB, and RhoC also appears to have a stronger ability to
activate ROCK in epithelial cells (Kaibuchi et al., 1999; Sahai
and Marshall, 2002a, b).
Here, we investigated whether RhoC promotes invasion
ability in a human melanoma cell line through the PI3K/Akt
and ROCK signaling pathways.
RESULTS
RhoC promotes invasion of WM35 cells
The WM35 cell line is derived from an early, RGP of human
melanoma, and is neither invasive nor metastatic. To study
the contribution of RhoC in metastatic behavior in melano-
ma, we constructed stable derivatives that overexpressed
RhoC. WM35 cells were transduced with either a retroviral
vector carrying a full-length human RhoC gene together with
green fluorescent protein (GFP), or a control retroviral vector
carrying GFP only. Cells potentially expressing high levels of
RhoC were selected for GFP expression with several rounds
of FACS. Cytometric analysis showed that 495% of the
sorted cells contained GFP, and quantitative real-time reverse
transcription-PCR showed more than 10-fold increase in
RhoC RNA expression in the WM35RhoC cells compared to
the control WM35GFP or parent WM35 cells (Figure S1).
We investigated whether RhoC promoted invasion of the
WM35 cells, using Matrigel chamber invasion assays.
WM35RhoC cells showed 39% invasion efficiency, whereas
WM35 and WM35GFP cells showed less than 2% invasion
efficiency (Figure 1).
The ADP ribosyl transferase, C3, specifically inhibits Rho
protein functions by selectively ADP-ribosylating Rho proteins
on asparagine residue 41 (Stasia et al., 1991; Bourmeyster
et al., 1992). C3 has only low affinity for other members of the
Rho family such as Cdc42 and Rac1. Treatment of
WM35RhoC cells with the Rho inhibitor C3 transferase
(30mg/ml) blocked the invasion of WM35RhoC cells but
slightly promoted invasion of the control cells (Figure 1c).
RhoC upregulates pAkt in a Rho- and PI3K-dependent manner
As phosphorylation of Akt is essential for maximal activation,
the expression of phosphorylated Akt (pAkt) is a good
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Figure 1. Invasion assays of WM35-derived cells. Matrigel invasion
chambers were used to compare invasive ability. (a) Assays were performed
with 72 hours incubation. Pictures of the bottom membranes were taken at
original magnification 400. (b) Quantification of invasion ability. Assays
were performed with 48 hours incubation. (c) The effects of Rho inhibitor, C3
transferase treatment (30 mg/ml for 48 hours) on invasiveness of WM35RhoC
and control cells. Pictures of the top and bottom membranes were taken at
original magnification  100. Experiments have been repeated twice.
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indication of active forms of Akt. We performed Western
blotting to determine the pAkt expression in these cells
and found that RhoC upregulated pAkt-Ser473 without
significantly affecting expression levels of total Akt1, Akt2,
or Akt3 (Figure 2a and Figure S2). Treatment of WM35RhoC
cells with C3 transferase downregulated the pAkt signal
as early as 1 hour following treatment, indicating that
the enhanced phosphorylation signal was due to RhoC
signaling (Figure 2b). Also, treatment of WM35RhoC cells
with the PI3K inhibitor, LY294002, downregulated the
pAkt signal (Figure 2c), indicating that the phosphory-
lation of Akt was dependent on PI3K signaling. This suggests
that the effects of RhoC overexpression are mediated via
PI3K/AKT.
Inhibition of the PI3K/Akt pathway blocks RhoC-dependent
invasion
To assess the involvement of the PI3K/Akt pathway in RhoC-
mediated invasion, we performed invasion assays in WM35
cells treated with either Akt inhibitor III or the PI3K inhibitor
(LY294002). Akt inhibitor III partially suppressed invasion
on WM35RhoC cells from 39 to 21% (P-value¼0.033).
But this inhibitor had no effect on the low invasion efficiency
of WM35 or WM35GFP cells (Figure 3). Similarly, the PI3K
inhibitor suppressed invasion of WM35RhoC (from 40.5
to 23.5%), but did not affect WM35 or WM35GFP cells
(Figure 4).
Inhibition of ROCK decreases invasion in WM35RhoC cells, but
does not affect pAkt expression
To study whether RhoC promoted invasion through ROCK
in WM35 cells, we performed invasion assays in cells
treated with the ROCK inhibitor (Y27632). We found that
inhibition of ROCK decreased cell invasion in WM35RhoC
cells (43 to 27%, P¼0.026; Figure 5a). However, unexpec-
tedly, Western blot analysis showed that the ROCK inhibitor
did not affect the level of phosphorylated Akt in WM35RhoC
cells (Figure 5b).
Inhibition of both ROCK and Akt together decreases invasion
further in WM35RhoC cells
To study whether RhoC promoted invasion through ROCK
and PI3K/Akt in the same or separate pathways, we
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Figure 2. Western blot analysis of pAkt expression. (a) Samples from WM35,
WM35GFP, and WM35RhoC cells were probed with antibodies to the
indicated proteins. (b) Samples from WM35RhoC cells were analyzed after
treatment with or without C3 transferase (Rho inhibitor) for the indicated time.
(c) Samples were analyzed after treatment with or without LY294002 (PI3K
inhibitor) for 18 hours. Experiments have been repeated three times.
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Figure 3. The effects of Akt inhibitor III treatment on invasiveness of
WM35RhoC and control cells. Invasion assays were performed with or
without Akt inhibitor III (5 mM for 48 hours). (a) Quantification of invasion
efficiency. (b) Pictures of top and bottom membranes were taken at original
magnification  100. Data summarize four experiments.
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Figure 4. The effects of PI3K inhibitor (LY294002) treatment on invasiveness
of WM35RhoC and control cells. Invasion assays were performed with or
without LY294002 (10 mM for 48 hours). (a) Quantification of invasion
efficiency of WM35RhoC cells. (b) Pictures of top and bottom membranes
were taken at original magnification  100. Data summarize three
experiments.
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performed invasion assays in cells treated with the Akt or
ROCK inhibitor alone or together. We found that treatment
with both inhibitors together decreased cell invasion effi-
ciency more than treatment with either inhibitor alone in
WM35RhoC cells (Figure 6). The invasion efficiency for
combination treatment was statistically significantly different
from that for either Akt or ROCK inhibitor treatment alone
(Figure 6).
DISCUSSION
RhoC was shown using DNA arrays to be expressed at a
higher level in metastastic melanoma cells compared with
their poorly metastatic counterparts (Clark et al., 2000).
Furthermore, enforced expression of RhoC in A375 cells
induced metastasis, whereas inhibitory Rho mutants sup-
pressed both invasion and metastasis (Clark et al., 2000).
However, it is still unclear how RhoC promotes metastasis
and what are the downstream targets.
To better understand these questions, we established
stable transfectants overexpressing RhoC, using a human
RGP melanoma cell line, WM35. Overexpression of RhoC
enhanced invasive ability of WM35, and this increased
invasion was abolished by the Rho inhibitor, C3 (Figure 1).
Our data show that overexpression of RhoC in an RGP cell
line is sufficient to increase invasion ability, consistent with
previous studies of the VGP melanoma cell line, A375 (Clark
et al., 2000).
To determine whether RhoC promotes invasion through a
PI3K/Akt pathway, we examined the effects of a PI3K
inhibitor or an Akt inhibitor on invasion ability. The increased
invasion ability seen with WM35RhoC cells was partially
inhibited by the PI3K or Akt inhibitors, whereas these
inhibitors had no effects on control cells (Figures 3 and 4).
Similar experiments with ROCK inhibitor showed that RhoC-
promoted invasion is also partially dependent on ROCK
activity (Figure 5). Further, treatment with Akt and ROCK
inhibitors together decreased cell invasion efficiency more
than treatment with either individual inhibitor (Figure 6).
These results suggest that RhoC promotes invasion in part
through separate PI3K/Akt pathway and ROCK signals in a
human primary melanoma cell line.
Upregulation of total pAkt has been associated with
severely dysplastic nevi and metastatic melanomas compared
with normal or mildly dysplastic nevi (Dhawan et al., 2002).
A recent study indicated two distinct mechanisms for
activation of Akt3 in melanomas: (1) increase of Akt3 gene
copy number and (2) decrease of PTEN activity (Stahl et al.,
2004). Here, we demonstrated that overexpression of RhoC
in WM35 cells upregulated pAkt (Ser473/474/472) (Figure
2a). Thus, the overexpression of RhoC associated with more
aggressive melanoma (Clark et al., 2000; Collisson et al.,
2003), may provide a third mechanism contributing to
upregulation of pAkt in these tumors. We also showed that
upregulation of pAkt by RhoC can be blocked by treatment
with either the Rho inhibitor (C3 transferase) or PI3K inhibitor
(LY294002), but not ROCK inhibitor (Figure 2b and c). These
data imply that RhoC activates the PI3K/Akt pathway
independent of ROCK signals. As RhoA signaling via ROCK
has previously been shown to either activate or downregulate
PI3K/Akt signaling, depending on the cell type and cellular
context (Bourguignon et al., 2003; Li et al., 2005), our results
add further complexity to the regulation of PI3K/Akt activity
by Rho GTPases, indicating that the consequences of Rho and
ROCK signaling likely are cell type and/or cellular context
dependent.
RhoC-induced invasion has also been reported in inflam-
matory breast cancer, but, in this case, the mitogen-activated
protein kinase pathway and not the PI3K pathway was found
to be responsible (van Golen et al., 2002). It is possible that
RhoC might induce different pathways in breast cancer and
melanoma owing to the differences in basal levels of
mitogen-activated protein kinase activity. Satyamoorthy
et al. (2003) have demonstrated constitutive mitogen-
activated protein kinase activation in melanoma, apparently
due both to BRAF mutations and autocrine growth factor
stimulation (Satyamoorthy et al., 2003). All the melanoma
cell lines they tested had constitutively high level of
phosphorylated ERK expression even in the absence of serum
in culture, regardless of their progression stages, including the
WM35 cell line used in this study (Satyamoorthy et al., 2003).
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Figure 5. The effects of ROCK inhibitor (Y27632) treatment on invasion and
pAkt expression in WM35RhoC cells. (a) Invasion assays were performed
with or without Y27632 (40 mM for 48 hours). Data summarize three
experiments. (b) WM35RhoC cells were treated with or without Y27632 at the
indicated concentration for 24 hours before being harvested for Western blot.
Data represent four different experiments.
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Figure 6. The effects of treatment with both Akt and ROCK inhibitors
combined on invasion. Invasion assays were performed as in Figures 3 and 5.
WM35RhoC cells were treated with Akt inhibitor III (5 mM) and ROCK
inhibitor (Y27632, 40mM) alone or combined for 48 hours. The results
represent two experiments. P-values were calculated as indicated for each
column versus treatment with AktþROCK inhibitor.
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As WM35 cells have little invasion ability, these data also
suggest that activation of mitogen-activated protein kinase
alone in melanoma cells is not sufficient to promote invasion.
In summary, our study demonstrates that RhoC promotes
invasion in human melanoma through separate PI3K/Akt and
ROCK pathways, operating in parallel, not in series (Figure 7).
This provides a novel insight into the mechanisms by which
overexpression of RhoC enhances invasion and probably
tumor progression in human melanoma.
MATERIALS AND METHODS
Constructs
Retroviral constructs pMIG-RhoC-IRES-GFP (RhoC) and pMIG-
DNRhoA-IRES-GFP (DNRhoA) were kindly provided by Dr Richard
Hynes (Massachusetts Institute of Technology). Retroviral construct
pMIG (GFP) was made by re-ligating the RhoC construct after
excising the RhoC gene.
Reagents
Human recombinant C3 transferase protein was purchased from
Cytoskeleton (Denver, CO). Akt inhibitor III, LY294002 (PI3K
inhibitor), and Y27632 (ROCK inhibitor) were purchased from
Calbiochem (a brand of EMD Biosciences Inc., San Diego, CA).
Cell lines and culture conditions
Cells were maintained in RPMI medium 1640 (Invitrogen, Grand
Island, NY) with 10% fetal bovine serum (Gemini Bio-Products Inc.,
Woodland, CA) at 371C with 5% CO2. The primary, RGP, human
melanoma cell line, WM35, was obtained from Dr Meenhard Herlyn
(Wistar Institute). The retroviral constructs were transfected into
293T-based amphotropic packaging cells and melanoma cells were
infected as described (Kinsella and Nolan, 1996; Clark et al., 2000).
Cells were sorted three rounds according to their GFP levels by the
FACS core in the Cancer Center of the UCDHSC. We have checked
RhoC expression during experiments and the cells have been
overexpressing RhoC. In addition, we also checked fluorescence of
GFP, which is on the same vector as RhoC all the time, and the cells
remain fluorescent throughout the study.
In vitro invasion assay
Matrigel invasion chambers (8-mm Transwell Biocoat) were used
according to the manufacturer’s protocol (BD Biosciences, Bedford,
MA). Briefly, 1–2 105 cells/well were seeded into invasion cham-
bers in a 24-well plate, and incubated at 371C for 48 or 72 hours.
Duplicate chambers were used for staining the cells either on the
bottom or top of the membranes. Cells on the top surface of the
membrane were removed by scrubbing with a cotton swab in order
to stain and visualize the cells on the bottom. Conversely, cells on
the bottom surface of the membrane were removed in order to stain
and visualize the cells on the top. The remaining cells were fixed and
then stained with hematoxylin stain (Harris Hematoxylin Solution
Modified; Sigma Diagnostics, St Louis, MO). Cells were viewed and
counted using a Nikon Eclipse TS100 inverted microscope at  100
or  400 magnification (Melville, NY). Pictures of four quadrants of
stained chamber membranes were taken with a Nikon COOLPIX
digital camera. Pictures were then quantified by NIH Image/Image J
to obtain the cell density multiplied by the total area to yield the
number of cells on the top or bottom. The percent invasion
efficiency was calculated as follows: number of cells on the
bottom/(number of cells on the bottomþ number of cells on the
top) 100. The reported invasion efficiencies are the average of two
or three independent experiments.
For inhibitor experiments, reagents were added to the top and
bottom chambers 1–2 hours after plating the cells and were
maintained in the chambers for the entire incubation time.
For statistical analysis, two-tailed paired t-test of Excel was used.
Immunoblot
Cells were cultured in 10 cm dishes to about 70% confluency,
washed once with phosphate-buffered saline (PBS), and lysed
directly in the dish with 0.5 ml of 1 Laemmli sample buffer (Bio-
Rad, Hercules, CA). Lysates were heated at 951C for 10 minutes and
then clarified by centrifugation at 13,200 g for 5 minutes. Samples
(50 mg protein) were electrophoresed on SDS-PAGE 4–15% acryla-
mide gradient gels (Bio-Rad, Hercules, CA), and transferred to PVDF
membranes using a Transblot SD Semi-Dry Transfer Cell apparatus
(Bio-Rad, Hercules, CA) at 15 V for 25 minutes. Membranes were
probed with primary antibodies in PBS–5% nonfat dry milk powder,
washed with PBS for 2 5 minutes, Tris-buffered saline/Tween for
2 10 minutes, then PBS for 2 5 minutes, and incubated with
horseradish peroxidase-conjugated secondary antibody in PBS–5%
nonfat dry milk powder. Blots were developed with horseradish
peroxidase substrate (West Pico or Femto developing solutions,
Pierce, Rockford, IL) for 5 minutes at room temperature, and
analyzed using a Chemi-doc chemoluminescence detector
(Bio-Rad, Hercules, CA). The following antibodies were used:
anti-phospho-Akt-Ser473/474/472 rabbit polyclonal antibody
(Cell Signaling Technology Inc., Beverley, MA, or Biosciences
Pharmingen, San Diego, CA), anti-Akt1 (BD Transduction Labora-
tories, San Jose, CA), anti-Akt2 and anti-Akt3 (Upstate, Lake Placid,
NY), anti-actin mouse monoclonal antibody (EMD Biosciences Inc.,
San Diego, CA), horseradish peroxidase-conjugated goat anti-rabbit
IgG (Transduction Laboratories, Lexington, KY), or horseradish
peroxidase-conjugated goat anti-mouse IgM (EMD Biosciences
Inc., San Diego, CA). We used 1:1,000 dilution for all the primary
antibodies except anti-actin at 1:10,000, and 1:2,500 dilution for the
secondary antibodies.
For inhibitor experiments, cells were seeded with RPMI
1640þ 10% fetal bovine serum in six-well plates for 1–5 hours
before the medium was changed to fresh medium with or without
the indicated inhibitors.
All experiments have been performed following the UCHSC
institution rules.
RhoC
ROCKPI3K
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Figure 7. Diagram of proposed pathways.
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